Leniolisib

Phase 2Recruiting

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

PIDs Linked to PI3K

Conditions

PIDs Linked to PI3K

Trial Timeline

Apr 29, 2025 → Apr 13, 2029

NCT ID

NCT06990529

About Leniolisib

Leniolisib is a phase 2 stage product being developed by Pharming Group for PIDs Linked to PI3K. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06990529. Target conditions include PIDs Linked to PI3K.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06990529	Phase 2	Recruiting	Apr 29, 2025	Apr 13, 2029	PIDs Linked to PI3K
NCT05693129	Phase 3	Active	Aug 30, 2023	Oct 28, 2026	APDS
NCT05438407	Phase 3	Active	Feb 1, 2023	Dec 30, 2025	APDS

Other Products from Pharming Group

LeniolisibPhase 3